June 7, 2016
Takeda Pharmaceutical’s potassium-competitive acid blocker Takecab (vonoprazan) left the strongest impression on physicians in April through a series of promotional channels, including drug reps and seminars, a monthly survey showed. According to the survey conducted by Anterio, Takecab topped the...read more